多发性硬化的联合治疗进展

New Advancement in the Combination Therapy of Multiple Sclersis

免疫调节药物在治疗多发性硬化上取得了很好的效果,降低了复发率,延缓了残疾进展,减少了磁共振成像病灶数量或缩小了其体积。但仅部分有效,许多患者在服药期间疾病仍快速进展,故有学者提出联合用药方案。许多临床试验用两种或两种以上不同机制的药物治疗多发性硬化患者,以此来评定其效果与安全性。该文就多发性硬化联合治疗的合理性及临床研究现状等进行综述。

Immunomodulating agents have beneficial effects in the treatment of multiple sclerosis,which decreases the frequency of relapses,delays the progression of disability,and reduces magnetic resonance imaging lesion quantity or shrinks the lesion volume. Despite the efficacy of these agents,many patients continue to show progression of the disease. Therefore,clinicians have proposed a variety of combinations of agents in an attempt to decrease disease activity. A number of clinical trials applying two or more drugs with different mechanisms for the treatment of multiple sclerosis have been done,in order to assess the effectiveness and safety. Here is to make a review of the rationale and clinical research of combination therapies for multiple sclerosis.